ES2083348T1 - Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)-metoxi-1,3-propandiol. - Google Patents

Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)-metoxi-1,3-propandiol.

Info

Publication number
ES2083348T1
ES2083348T1 ES95111319T ES95111319T ES2083348T1 ES 2083348 T1 ES2083348 T1 ES 2083348T1 ES 95111319 T ES95111319 T ES 95111319T ES 95111319 T ES95111319 T ES 95111319T ES 2083348 T1 ES2083348 T1 ES 2083348T1
Authority
ES
Spain
Prior art keywords
metoxi
dihidro
purin
oxo
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES95111319T
Other languages
English (en)
Other versions
ES2083348T3 (es
Inventor
John J Nestor
Scott W Womble
Hans Maag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23079211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2083348(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of ES2083348T1 publication Critical patent/ES2083348T1/es
Application granted granted Critical
Publication of ES2083348T3 publication Critical patent/ES2083348T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE PRESENTAN UN ESTER DE L-MONOVALINA DERIVADO DEL 2-(2-AMINO1,6-DIHIDRO-6-OXO-PURIN-9-YL)METOXI-1,3-PROPANEDIOL Y SUS SALES FARMACOLOGICAMENTE ACEPTABLES QUE TIENEN VALOR COMO AGENTES ANTIVIRALES CON UNA ABSORCION MEJORADA.
ES95111319T 1994-07-28 1995-07-19 Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)metoxi-1,3-propandiol. Expired - Lifetime ES2083348T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189394A 1994-07-28 1994-07-28

Publications (2)

Publication Number Publication Date
ES2083348T1 true ES2083348T1 (es) 1996-04-16
ES2083348T3 ES2083348T3 (es) 1999-08-01

Family

ID=23079211

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95111319T Expired - Lifetime ES2083348T3 (es) 1994-07-28 1995-07-19 Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)metoxi-1,3-propandiol.

Country Status (33)

Country Link
EP (1) EP0694547B1 (es)
JP (1) JP3090305B2 (es)
KR (1) KR100358626B1 (es)
CN (1) CN1045089C (es)
AT (1) ATE179173T1 (es)
AU (1) AU697107B2 (es)
BR (1) BR9503468A (es)
CA (1) CA2154721C (es)
CO (1) CO4410181A1 (es)
CY (2) CY2180B1 (es)
CZ (1) CZ290511B6 (es)
DE (3) DE10299032I2 (es)
DK (1) DK0694547T3 (es)
ES (1) ES2083348T3 (es)
FI (1) FI112080B (es)
GR (2) GR960300021T1 (es)
HK (1) HK1012339A1 (es)
HU (1) HU216867B (es)
IL (1) IL114735A (es)
LU (1) LU91136I2 (es)
MA (1) MA23631A1 (es)
MY (1) MY114393A (es)
NL (1) NL300071I2 (es)
NO (2) NO312899B1 (es)
NZ (1) NZ272652A (es)
PE (1) PE32296A1 (es)
PL (1) PL180609B1 (es)
RU (1) RU2133749C1 (es)
SA (1) SA95160158B1 (es)
TR (1) TR199500895A2 (es)
TW (1) TW434242B (es)
UY (1) UY24006A1 (es)
ZA (1) ZA956228B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
WO1997027194A1 (en) * 1996-01-26 1997-07-31 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
ATE222909T1 (de) * 1996-01-26 2002-09-15 Hoffmann La Roche Verfahren zur herstellung von purin-derivaten
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
CA2572577C (en) * 1997-02-10 2011-04-05 Medivir Ab Synthesis of acyclic nucleoside derivatives
US6184376B1 (en) 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
PT988304E (pt) * 1997-08-15 2001-10-31 Medivir Ab Analogos de nucleosidos tais como os antivirais que contem inibidores de transcritase reversa retroviral e de adn-polimerase do virus da hepatite b (hbv)
AU1711599A (en) * 1997-12-19 1999-07-12 Bristol-Myers Squibb Company Prodrugs of lobucavir and methods of use
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
KR20030015655A (ko) * 2001-08-17 2003-02-25 한미약품공업 주식회사 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물
DE60328675D1 (de) * 2002-04-23 2009-09-17 Aventis Pharma Inc 3-(substitutierte amino)-1h-indole-2-carbonsäureester und 3-(substitutierte amino)-benzoäbüthiophen-2-carbonsäureester verbindungen als inhibitoren der interleukin-4 genexpression
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
US20040224916A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1660499A1 (en) * 2003-08-28 2006-05-31 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
NZ553263A (en) * 2004-07-19 2010-06-25 Biocon Ltd Insulin-oligomer conjugates, formulations and uses thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ZA200702234B (en) * 2006-03-21 2008-07-30 Cipla Ltd Preparation of ester of purine derivatives
CN102014638A (zh) 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
EP2714691B1 (en) * 2011-05-31 2016-09-07 Pharmathen S.A. Process for the preparation of 2-amino-9-((2-phenyl-1,3-dioxan-5-yloxy)methyl)-1h-purin-6(9h)-one compound useful in the preparation of valganciclovir
KR102312533B1 (ko) 2021-02-24 2021-10-15 주식회사 이웅 자동 스패너

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
FI91959C (fi) * 1984-12-12 1994-09-12 Syntex Inc Menetelmä valmistaa alkoksimetyylieetteri- ja alkoksimetyyliesterijohdoksia
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
JP2788084B2 (ja) * 1988-12-19 1998-08-20 ザ ウエルカム フアウンデーシヨン リミテツド 抗ウイルス化合物

Also Published As

Publication number Publication date
KR960004345A (ko) 1996-02-23
FI953592A0 (fi) 1995-07-27
PE32296A1 (es) 1996-08-07
RU95113148A (ru) 1997-06-27
JPH0841061A (ja) 1996-02-13
IL114735A0 (en) 1995-11-27
EP0694547B1 (en) 1999-04-21
CY2004003I1 (el) 2009-11-04
HU9502238D0 (en) 1995-09-28
EP0694547A3 (en) 1996-06-05
CA2154721A1 (en) 1996-01-29
EP0694547A2 (en) 1996-01-31
FI953592A (fi) 1996-01-29
RU2133749C1 (ru) 1999-07-27
SA95160158B1 (ar) 2006-05-20
IL114735A (en) 1998-06-15
MY114393A (en) 2002-10-31
ATE179173T1 (de) 1999-05-15
PL309812A1 (en) 1996-02-05
DK0694547T3 (da) 2000-01-03
DE10299032I2 (de) 2006-06-14
FI112080B (fi) 2003-10-31
CZ193995A3 (en) 1996-02-14
NO952977L (no) 1996-01-29
BR9503468A (pt) 1996-02-27
CO4410181A1 (es) 1997-01-09
JP3090305B2 (ja) 2000-09-18
MA23631A1 (fr) 1996-04-01
CN1122804A (zh) 1996-05-22
CA2154721C (en) 2001-01-02
DE694547T1 (de) 1996-10-24
DE69509173D1 (de) 1999-05-27
NO952977D0 (no) 1995-07-27
KR100358626B1 (ko) 2003-01-14
TR199500895A2 (tr) 1996-06-21
CZ290511B6 (cs) 2002-08-14
NO312899B1 (no) 2002-07-15
NL300071I1 (nl) 2002-02-01
PL180609B1 (pl) 2001-03-30
AU2719595A (en) 1996-02-08
UY24006A1 (es) 2001-07-31
GR960300021T1 (en) 1996-04-30
ZA956228B (en) 1996-02-22
TW434242B (en) 2001-05-16
AU697107B2 (en) 1998-09-24
ES2083348T3 (es) 1999-08-01
CN1045089C (zh) 1999-09-15
NO2003001I2 (no) 2007-06-11
HU216867B (hu) 1999-09-28
CY2004003I2 (el) 2009-11-04
GR3030678T3 (en) 1999-11-30
HUT73246A (en) 1996-07-29
LU91136I2 (fr) 2005-07-06
DE69509173T2 (de) 1999-10-21
HK1012339A1 (en) 1999-07-30
DE10299032I1 (de) 2003-01-23
NL300071I2 (nl) 2002-03-01
NZ272652A (en) 1996-12-20
CY2180B1 (en) 2002-08-23

Similar Documents

Publication Publication Date Title
ES2083348T3 (es) Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)metoxi-1,3-propandiol.
BR9801775B1 (pt) fibra àptica tendo uma inclinaÇço de dispersço baixa na regiço de amplificador de Érbio.
DE60021099D1 (de) Transdermale, in form einer haftschicht ausgebildete zweifachmedikamenten-verabreichungsvorrichtung
DE60143477D1 (de) Verminderung der nebenwirkungen bei der oxybutynin-therapie
FI915152A (fi) Synergism hos inhibitorer foer reverserade transkriptaser i hiv.
MX9300550A (es) Estructura de fibra absorbente.
TR28377A (tr) Lif cekme jetlerinin temizlenmesi.
DE69114684D1 (de) Faserschlichtemittel.
ES2105074T3 (es) Compuestos basados en 3,4-diaril-(5h)-furan-2-ona, con actividad fungicida.
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
GT199500039BA (es) Compuestos ariltios
DK0612469T3 (da) Præparat med akaricid virkning
AR027349A1 (es) Derivados de amidas heterociclicas
FR2795878B1 (fr) Source laser avec filtrage integre de l'emission spontanee amplifiee
ES2033620T1 (es) Apero de cultivo del suelo.
ES2189108T3 (es) Nuevas oxazinas dissustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2107607T3 (es) Tiazolilpirroles que tienen una actividad fungicida.
DE69107160D1 (de) Stromversorgungsanordnung.
ECSP951495A (es) Derivado de 2-(2-amino-1,6- dihidro-6-oxo- purin-9-il) metoxi-1,3- propan-diol
ES2049696T3 (es) Utilizacion de una amida como agente espesante y composicion que la contiene.
ES1043884Y (es) Butaca con mesa de trabajo posterior.
ITTO910671A1 (it) Procedimento per effettuare una saldatura laser con effetto estetico del giunto.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 694547

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: VALGANCICLOVIR (VALCYTE)

Spc suppl protection certif: C200200029

Filing date: 20021113

SPCG Supplementary protection certificate granted

Free format text: VALGANCICLOVIR (VALCYTE)

Spc suppl protection certif: C200200029

Filing date: 20021113

Expiry date: 20160920

Effective date: 20040309